Exicure and Adbiotech to Co-Develop Burixafor for Sickle Cell, AML and Solid Tumors
Exicure has signed a co-development deal with Adbiotech to test its CXCR4 antagonist Burixafor in combination therapies for sickle cell disease, acute myeloid leukemia and solid tumors. Adbiotech will run in vivo and preclinical studies while Exicure supplies Burixafor and leads clinical and regulatory strategy toward potential IND-enabling studies.
1. Co-Development Agreement Details
On April 22, 2026, Exicure entered into a co-development agreement with Korea’s Adbiotech to explore combination therapies involving Burixafor (GPC-100). The collaboration will evaluate in vivo validation studies across sickle cell disease, acute myeloid leukemia and various solid tumors, with future plans for IND-enabling studies and clinical trials.
2. Partner Roles and Study Focus
Under the deal, Adbiotech will conduct all in vivo and preclinical validation work, including translational research in hematologic and solid tumor models. Exicure will provide Burixafor supply and spearhead clinical development and regulatory strategy, coordinating program advancement and funding efforts.
3. Clinical Profile and Next Steps
Burixafor completed a Phase 2 trial in multiple myeloma in 2025, demonstrating a foundation for broader hematologic application. The parties intend to finalize a definitive agreement detailing budget, intellectual property and commercialization, then secure funding to advance selected programs into IND-enabling studies.